IL6 and congenital rubella syndrome: The interleukin-6 (IL-6) receptor antagonist tocilizumab is an important treatment for patients with CRS, but it does not cross the blood–brain barrier and tocilizumab may precipitate ICANS in high-risk patients due to the transient increase in the systemic and central nervous system (CNS) IL-6 levels following tocilizumab administration (9, 10).